

S2 Table. Comparison of baseline and tumor characteristics of surveillance group according to surveillance interval

Variable	Surveillance within 6 mo (n=70, 55.1%)	Surveillance with 6-12 mo (n=57, 44.9%)	p-value ^{a)}
Age (yr)	60.9 ± 9.9	59.8 ± 11.8	0.584
Male sex	53 (75.7)	48 (84.2)	0.238
Follow-up duration (mo)	29.2 ± 16.1	23.1 ± 14.2	0.025
ECOG			
0/1	63 (96.9)	50 (100.0)	0.211
≥2	2 (3.1)	0	
Etiology			
HBV	58 (82.9)	41 (71.9)	0.245
HCV	9 (12.9)	8 (14.0)	
HBV and HCV	0	0	
Alcohol	2 (2.%)	4 (7.0)	
Others	1 (1.4)	4 (7.0)	
Cirrhosis	63 (90.0)	43 (75.4)	0.028
Anti-viral therapy			
HBV	52 (74.3)	31 (54.4)	0.028
HCV	1 (1.4)	5 (8.8)	
Platelet (×10 ³ /mm ³)	103.9 ± 54.3	119.7 ± 54.3	0.105
ALT (IU/L)	36.7 ± 22.7	38.0 ± 24.1	0.746
Albumin (g/dL)	3.9 ± 0.5	4.0 ± 0.5	0.793
Bilirubin (mg/dL)	1.2 ± 2.0	0.9 ± 0.6	0.283
PT INR	1.2 ± 0.2	1.1 ± 0.2	0.272
Creatinine (mg/dL)	0.9 ± 0.5	0.9 ± 0.4	0.789
Child-Pugh class			
A	62 (88.6)	50 (87.7)	0.882
B/C	8 (11.4)	7 (12.3)	
AFP (ng/mL)			
≤ 20	47 (67.1)	30 (52.6)	0.228
21-400	19 (27.1)	21 (36.8)	
> 400	4 (5.7)	6 (10.5)	
Type of HCC			
Nodular	69 (98.6)	53 (93.0)	0.107
Infiltrative	1 (1.4)	4 (7.0)	
Tumor size (cm)	2.5 ± 1.3	3.6 ± 3.2	0.015
Portal vein thrombosis	3 (4.3)	3 (5.3)	0.796
Extra-hepatic metastasis	1 (1.4)	2 (3.5)	0.443
BCLC stage			
0/A	60 (85.7)	42 (73.7)	0.182
B	5 (7.1)	9 (15.8)	
C	5 (7.1)	6 (10.5)	
D	0	0	
mUICC stage			
I	47 (67.1)	33 (57.9)	0.169
II	17 (24.3)	11 (19.3)	
III	5 (7.1)	11 (19.3)	
IVA	0	0	
IVB	1 (1.4)	2 (3.5)	
Treatment modality			
Surgical resection	3 (4.3)	4 (7.0)	0.330

RFA	19 (27.1)	9 (15.8)
RFA+TACE	13 (18.6)	8 (14.0)
TACE	33 (47.1)	36 (63.2)
TACE+PEIT	1 (1.4)	0
Sorafenib	1 (1.4)	0
Supportive care	0	0

Values are presented as mean±standard deviation or number (%). ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; HCV, hepatitis C virus; ALT, alanine transferase; PT INR, prothrombin time international normalized ratio; AFP, α -fetoprotein; HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer; mUICC, modified Union for International Cancer Control; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; PEIT, percutaneous ethanol injection therapy. ^{a)}p-value for comparisons between “surveillance interval within 6-months” group and “surveillance interval with 6-12 months” group.